Contents
Current Pharmaceutical Design, Volume 20 - Number 42
Editorial
Editorial (Thematic Issue: Combined Cancer Therapy)
, 20(42): 6511 - 6512Jasminka Pavelic
DOI: 10.2174/1381612820666140826154834
Combining Oncolytic Virotherapy and Cytotoxic Therapies to Fight Cancer
, 20(42): 6513 - 6521Cristina Fillat, Maria Victoria Maliandi, Ana Mato-Berciano and Ramon Alemany
DOI: 10.2174/1381612820666140826152420
Anti-Metastatics: An Overview of Drug Candidates in Current Pipelines
, 20(42): 6522 - 6528Anne Schaap-Nutt, Dane A. Thyssen, David W. Drell and Frank Entschladen
DOI: 10.2174/1381612820666140826152610
Oxidative Stress and Antioxidants in Carcinogenesis and Integrative Therapy of Cancer
, 20(42): 6529 - 6542Lidija Milkovic, Werner Siems, Renate Siems and Neven Zarkovic
DOI: 10.2174/1381612820666140826152822
Attacking c-Myc: Targeted and Combined Therapies for Cancer
, 20(42): 6543 - 6554Huilin Huang, Hengyou Weng, Hui Zhou and Lianghu Qu
DOI: 10.2174/1381612820666140826153203
The Exploitation of Toll-like Receptor 3 Signaling in Cancer Therapy
, 20(42): 6555 - 6564Tanja Matijevic Glavan and Jasminka Pavelic
DOI: 10.2174/1381612820666140826153347
NCRNA Combined Therapy as Future Treatment Option for Cancer
, 20(42): 6565 - 6574Cornelia Braicu, Cristina Catana, George A. Calin and Ioana Berindan-Neagoe
DOI: 10.2174/1381612820666140826153529
Combined Cancer Therapy: Strategies to Overcome Acquired Aromatase Inhibitor Resistance
, 20(42): 6575 - 6583Susan B. Kesmodel, Gauri J. Sabnis, Saranya Chumsri and Angela M.H. Brodie
DOI: 10.2174/1381612820666140826153711
Immunotoxins Constructed with Ribosome-Inactivating Proteins and their Enhancers: A Lethal Cocktail with Tumor Specific Efficacy
, 20(42): 6584 - 6643Roger Gilabert-Oriol, Alexander Weng, Benedicta von Mallinckrodt, Matthias F. Melzig, Hendrik Fuchs and Mayank Thakur
DOI: 10.2174/1381612820666140826153913
A Comprehensive Review of Poorly Differentiated Neuroendocrine Carcinomas (pdNECs): a Niche to Find Novel Opportunities
, 20(42): 6644 - 6651Pablo Reguera, Ainhoa Madariaga and Enrique Grande
DOI: 10.2174/1381612820666140826154033
Pancreatic Cancer: Systemic Combination Therapies for a Heterogeneous Disease
, 20(42): 6660 - 6669Davide Melisi, Lorenzo Calvetti, Melissa Frizziero and Giampaolo Tortora
DOI: 10.2174/1381612820666140826154327
Mechanism-based Combinations with Pim Kinase Inhibitors in Cancer Treatments
, 20(42): 6670 - 6681Qingshan Yang, Lisa S. Chen and Varsha Gandhi
DOI: 10.2174/1381612820666140826154451
Curcumin in Combined Cancer Therapy
, 20(42): 6682 - 6696Koraljka Gall Troselj and Renata Novak Kujundzic
DOI: 10.2174/1381612820666140826154601
Combined Modality Therapy in Pancreatic Adenocarcinoma: Review and Updates on a Controversial Issue
, 20(42): 6697 - 6701Ludimila Cavalcante, David P. Kelsen and Kenneth H. Yu
DOI: 10.2174/1381612820666140826154724
Molecular Mechanisms Involved in the Control of Neurohypophyseal Hormones Secretion
, 20(42): 6702 - 6713M. Iovino, E. Guastamacchia, V.A. Giagulli, B. Licchelli, E. Iovino and V. Triggiani
DOI: 10.2174/1381612820666140905150730
The Molecular Mechanisms of TRAIL Resistance in Cancer Cells: Help in Designing New Drugs
, 20(42): 6714 - 6722Feng Wang, Junsheng Lin and Ruian Xu
DOI: 10.2174/1381612820666140929100735
Webmaster Contact: info@benthamscience.net